Profound Medical Corp. (TSE:PRN - Get Free Report)'s share price reached a new 52-week low during trading on Monday . The company traded as low as C$8.23 and last traded at C$8.23, with a volume of 2578 shares. The stock had previously closed at C$8.55.
Wall Street Analysts Forecast Growth
Separately, Raymond James upgraded shares of Profound Medical to a "strong-buy" rating in a research note on Saturday, November 9th.
View Our Latest Stock Analysis on Profound Medical
Profound Medical Price Performance
The firm has a market capitalization of C$197.87 million, a price-to-earnings ratio of -4.87 and a beta of 0.81. The company's 50 day moving average is C$10.17 and its 200-day moving average is C$11.07. The company has a current ratio of 6.12, a quick ratio of 14.98 and a debt-to-equity ratio of 20.05.
Insider Activity at Profound Medical
In related news, Director Arun Menawat Dr. purchased 20,000 shares of the stock in a transaction on Tuesday, December 10th. The shares were purchased at an average cost of C$10.65 per share, with a total value of C$213,000.00. Also, Senior Officer Thomas Michael Tamberrino purchased 13,333 shares of the stock in a transaction on Tuesday, December 10th. The stock was bought at an average cost of C$10.65 per share, for a total transaction of C$141,996.45. 8.62% of the stock is currently owned by company insiders.
About Profound Medical
(
Get Free Report)
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.
See Also
Before you consider Profound Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Profound Medical wasn't on the list.
While Profound Medical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
